Decoding Epigenetics: How DNA Methylation Inhibitors Are Changing the Face of Blood Cancer Care
The discovery of DNA methylation inhibitors represents one of the most significant advances in hematologic oncology of the past half-century. These remarkable agents, including azacitidine and decitabine, have fundamentally changed the understanding and treatment of blood cancers by targeting the epigenetic mechanisms that drive malignant transformation. According to the Decitabine Drug...
0 Commenti 0 condivisioni 3 Views 0 Anteprima